|
Do you want to stand out from dynamic generics competition and innovator pharma's entry? |
|
There are major shifts in the approach to the future opportunities for generic drugs:
·Global regulatory guidelines change.
·Blockbuster drug patents expire and IP infringements increase.
·Innovator Pharmas enter into generics market by M&A, strategic alliance and other partnerships.
·Innovative technology evolves in generics R&D and commercialization.
·Biosimilar is on emerging market.
These shifts have provided immens |
|
|
Figures and Facts for Generics |
|
·In China, generic drugs have a total market share of 97%.
·The peak of patent expiries will impact the key developed markets mostly in 2012.
·In 2011-2015, patent drugs with a value of over $77 billions are about to expire.
·The global generics market is estimated at about $225 billion in 2011. By 2016, it is expected that the value of the total global generics sector will have risen to $358 billion.
 |
Who Should Attend
CEOs, VPs, Directors, GMs, and Heads of: Business Development and Strategy, Product Development, Pharmaceutical Development, Sales & Marketing, R&D, Formulation, QA/QC, Clinical Research, In-Licensing, Out-Licensing, Regulatory Affairs, IPR from: |
|
From
Government agencies,Generic Manufacturers,Innovator Pharma Manufacturers,Biopharma Manufacturers,Life Sciences Companies,Drug Delivery Platform Providers，CRAMS,Analytical Laboratories,Ingredient and Material Suppliers,Machinery Manufacturers | |
|
|
Regulatory |
Market |
Technology |
| ·ANDA Updates and Generics Access in Assurance System |
| ·EU Healthcare Policy for Generics and Submission Procedure |
| ·SFDA (CTD) Format for Generics |
| ·Japan, India Regulatory System on Generics |
|
| ·Global and China Profitable Generics Landscape |
| ·Case Study: India Generic Drugs Development and Access and Penetration to USA and EU Market |
| ·Big Pharma’s IP Strategy, M&A prospect, strategic alliance, biosimilar strategy, etc. |
|
| ·New Formulation Technology and Strategy as Product Differentiation Strategy to Win the Competition: Controlled/Sustained, lipsome, nano technology, etc. |
| ·Impurities Research Methodology for Generic Drugs to Improve Quality |
|
|
7 Compelling Reasons to Attend |
|
·Delving into key trends of generics regulatory, market and technology
·Hearing in-depth presentations from 25+ global speakers under CPhI resources
·Getting on-spot answers to your critical business and technical challenges from 10+ Q&A sessions
·Covering 3 hot topics: updated regulatory environment, ever-changing market and alliance, evolving technology and commercialization
·Networking with and 120+ decision makers from 30+ China’s pharmaceutical companies and 20+ MNCs from Asia Pacific, America, Europe, etc.
·Brainstorming with industry leaders in 2 workshop and 2 leaders’ think tank
·Benefiting from case studies from leading generic pharma
|
|
|
|
Contact Us |
|
